Novo Nordisk has entered a $550 million multi-year partnership with Replicate Biosciences to develop therapies for obesity, type 2 diabetes, and other cardiometabolic disorders using Replicate’s self-replicating RNA (srRNA) platform. This technology enables patients' cells to produce therapeutic proteins with enhanced durability and tunability compared to existing RNA modalities. The collaboration complements Novo Nordisk’s expanding obesity treatment pipeline and builds on its prior RNA-focused investments, aiming to accelerate innovative metabolic treatments.